Search
Displaying 31–40 of 1095 results
-
Legacy Donor Spotlight: Dr. Debora Elliott Ward
Beacon StoriesDr. Debora Elliott Ward, a clinical psychologist living with retinitis pigmentosa, shares her journey of resilience, professional success, and commitment to supporting the Foundation Fighting Blindness by naming it a beneficiary in her estate plans.
-
Invisible Disability
I find it difficult to explain my eyesight to people. I have retinitis pigmentosa (RP), which is a condition that progressively causes vision loss. I am legally blind, my peripheral vision is very limited, and most of what I see is blurry.
-
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Eye on the CureDr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
Coping with Life Changes as Vision Declines
WellnessFor individuals who have been living with vision loss for some time, the journey often involves periods of adjustment. These moments can be deeply emotional, symbolizing a loss of independence or identity.
-
The Reality of an Invisible Disability: A Storytelling Series
“The Reality of an Invisible Disability,” a new storytelling content series dedicated to amplifying the voices of individuals experiencing vision loss, at any spectrum. This series aims to shed light on the invisible experience that unifies all disabilities, providing a platform for sharing personal and raw experiences, and fostering a community of understanding and advocacy.
-
Well-prepared estate plan brings peace of mind—knowing your loved ones are cared for and your wishes will be honored. It also offers a unique opportunity to leave a lasting impact on a cause important to you.
-
D.C. Metro Chapter Volunteer Opportunities
The DC Chapter is growing! Join our young professionals events for the Foundation Fighting Blindness, or become a part of the Young Professionals Committee.
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Research NewsDespite missing the primary endpoint, the treatment improved vision for some patients.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Research News
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
.png)
